Search clinical trials for: Atezolizumab [TECENTRIQ]

Total 759 results

Abramson Cancer Center at Penn Medicine
Genentech, Inc.

Recruiting

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Lung Cancer, Nonsmall Cell

United States
Exelixis

Recruiting

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Colorectal Cancer

United States, Poland, Australia, Belgium, France, Hong Kong, Korea, Republic of, Spain, Hungary, Singapore, New Zealand, Germany, Thailand, Taiwan, Portugal, United Kingdom
SCRI Development Innovations, LLC
Genentech, Inc.

Active, not recruiting

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Non-Small Cell Lung Cancer | Solid Tumor

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Active, not recruiting

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

Breast Cancer

United States
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Hoffmann-La Roche

Completed

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)

Triple-Negative Breast Cancer

France, Canada, Israel, Italy, Argentina, Brazil, China, Croatia, Germany, Greece, Slovakia, Turkey, Saudi Arabia, Japan, India, Spain, United States, Czechia, Romania, United Kingdom, Morocco, South Africa, Vietnam, Russian Federation
Institut für Klinische Krebsforschung IKF GmbH...
Roche Pharma AG; Thoraxklinik-Heidelberg gGmbH

Recruiting

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Non-small Cell Lung Cancer

Germany
Hoffmann-La Roche

Completed

A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

Colorectal Cancer

United States, France, Denmark, Spain
Treos Bio Limited
Mayo Clinic; Hoffmann-La Roche

Active, not recruiting

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Colorectal Cancer Metastatic

United States
Sanofi

Terminated

Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

Neoplasm

Spain, Taiwan, Italy, Czechia, United States, Belgium, Canada, Netherlands
Matthew Galsky
Genentech, Inc.

Completed

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

Urothelial/Bladder Cancer, Nos

United States
NeoImmuneTech
Roche Pharma AG

Active, not recruiting

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung | Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Non-Small Cell Lung Carcinoma

United States
European Organisation for Research and Treatment...
Hoffmann-La Roche; Leap Therapeutics, Inc.

Withdrawn

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC)

Esophageal Cancer | Hepatobiliary Neoplasm | Biliary Tract Cancer | GastroEsophageal Cancer
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
Genentech, Inc.

Active, not recruiting

A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Lymphocytic Leukemia, Chronic | Lymphoma, Non Hodgkin

United States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
Grand Hôpital de Charleroi
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Active, not recruiting

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer (R-IMMUNE)

Rectal Neoplasms

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland

Active, not recruiting

The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (HO151DLBCL)

NHL | DLBCL

Netherlands, Belgium
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Fundacion Oncosur

Recruiting

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Carcinoma, Small Cell Lung

Spain
Hoffmann-La Roche

Active, not recruiting

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Hepatocellular Carcinoma

China, Japan
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (SKYSCRAPER-07)

Esophageal Squamous Cell Carcinoma

United States, France, Spain, Australia, Korea, Republic of, Argentina, Belgium, China, Portugal, Taiwan, Japan, Germany, Poland, Thailand, United Kingdom, Switzerland, Turkey, Russian Federation, Morocco, Greece, Italy, New Zealand, South Africa and more
Fundación GECP

Active, not recruiting

Atezolizumab Plus Bevacizumab in First Line NSCLC Patients (TELMA)

Non Small Cell Lung Cancer

Spain
Genentech, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
Centre Leon Berard

Recruiting

A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments (ATEZOGIST)

Metastatic Gastrointestinal Stromal Tumor | Unresectable Gastrointestinal Stromal Tumor (GIST) | Locally Advanced Gastrointestinal Stromal Tumor (GIST)

France
H. Lee Moffitt Cancer Center and Research Institute
Genentech, Inc.

Recruiting

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

Cervical Cancer | Cervical Cancer Recurrent | Cervical Cancer Metastatic

United States
University of Colorado, Denver
Genentech, Inc.

Suspended

Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC

Squamous Cell Carcinoma of Head and Neck

United States
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer

Gynecologic Neoplasms

Spain, France, Australia, United Kingdom
Hoffmann-La Roche

Recruiting

A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab (IMbrave251)

Unresectable Hepatocellular Carcinoma

Canada, France, Korea, Republic of, China, Japan, Spain, Belgium, Croatia, Brazil, Austria, Italy, Costa Rica, Germany, Israel, Thailand, Turkey, Russian Federation, United Kingdom, Taiwan, Philippines, India, Chile, Finland, Greece, Sl... and more
Hoffmann-La Roche
Exelixis

Active, not recruiting

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy (CONTACT-01)

Carcinoma, Non-Small-Cell Lung

United States, France, Belgium, United Kingdom, Australia, Korea, Republic of, Austria, Italy, Portugal, Spain, Poland, Japan, Germany, Greece, Russian Federation
Hoffmann-La Roche

Terminated

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Stomach Neoplasms | Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Olivia Newton-John Cancer Research Institute
Austin Health; Roche Products Pty Limited; Ballarat Health Services

Active, not recruiting

Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy (FLUORO)

Follicular Lymphoma

Australia
Hoffmann-La Roche

Completed

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, France, United Kingdom, Hong Kong
Omico
Hoffmann-La Roche; The George Institute for Global Health, Australia

Recruiting

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients (MoST-TAP)

Solid Tumor, Adult

Australia
National Health Research Institutes, Taiwan
National Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaborators

Recruiting

Atezolizumab Plus Bevacizumab With HCC and HBV Infection

Carcinoma, Hepatocellular

Taiwan
Hoffmann-La Roche

Completed

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

Urothelial Carcinoma

Spain, United States, Korea, Republic of, Canada, United Kingdom, Czechia, Australia, Belgium, Brazil, China, Estonia, Finland, Greece, Hong Kong, Italy, Poland, Portugal, Slovenia, Mexico, Georgia, Russian Federation, Singapore, Th... and more
Yale University
Genentech, Inc.

Recruiting

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma

United States
ARCAGY/ GINECO GROUP
Hoffmann-La Roche

Active, not recruiting

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (ATALANTE)

Ovarian Cancer

Spain, Belgium, France, Germany, Austria, Czechia, Israel
University of Florida
Genentech, Inc.; Aveo Oncology Pharmaceuticals

Recruiting

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Soft Tissue Sarcoma | Breast Cancer | Pancreatic Adenocarcinoma | Ovarian Cancer | Prostate Cancer | Neuroendocrine Tumors | Vulvar Cancer | Bile Duct Cancer | Gall Bladder Cancer

United States
Hoffmann-La Roche

Active, not recruiting

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Gastric and Gastroesophageal Junction Carcinoma

China
Hoffmann-La Roche

Withdrawn

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma
Lokon Pharma AB

Recruiting

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

Pancreatic Cancer

United States
Washington University School of Medicine
Xcovery Holdings, Inc.

Active, not recruiting

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

United States
Genentech, Inc.
BioNTech SE

Active, not recruiting

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Melanoma | Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | Renal Cancer | Other Solid Cancers

United States, Belgium, Sweden, Germany, Canada, Spain, United Kingdom, Netherlands
Hoffmann-La Roche

Completed

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Metastatic Melanoma

France, Italy, Spain, Brazil, Latvia, Germany, Hungary, Switzerland
M.D. Anderson Cancer Center
Genentech, Inc.

Recruiting

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
The Methodist Hospital Research Institute
Genentech, Inc.

Not yet recruiting

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

Hepatocellular Carcinoma | Hepatocellular Cancer

United States
SOLTI Breast Cancer Research Group
Roche Pharma AG; Amgen

Active, not recruiting

Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer (PROMETEO)

Breast Cancer

Spain
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma (SKYSCRAPER-08)

Esophageal Cancer

Korea, Republic of, China, Hong Kong, Thailand, Taiwan
Fondazione Melanoma Onlus
Clinical Research Technology S.r.l.

Active, not recruiting

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

Melanoma

Italy

Search clinical trials for: Atezolizumab [TECENTRIQ]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations